Peel Hunt Maintains GBX 235.00 Target Price On Alumasc Group PLC (LON:ALU), Maintains “Buy” Rating; SEMLER SCIENTIFIC (SMLR) Sellers Increased By 57.89% Their Shorts

January 10, 2018 - By Danny Collins

SEMLER SCIENTIFIC INCORPORATED (OTCMKTS:SMLR) had an increase of 57.89% in short interest. SMLR’s SI was 3,000 shares in January as released by FINRA. Its up 57.89% from 1,900 shares previously. With 15,600 avg volume, 0 days are for SEMLER SCIENTIFIC INCORPORATED (OTCMKTS:SMLR)’s short sellers to cover SMLR’s short positions. It closed at $7.5 lastly. It is down 0.00% since January 10, 2017 and is . It has underperformed by 16.70% the S&P500.

Expert analysts at Peel Hunt have GBX 235.00 target price on Alumasc Group PLC (LON:ALU). Peel Hunt’s target price would indicate a potential upside of 36.23% from the company’s last stock price. The rating was revealed to investors in an analyst report on 10 January.

Among 3 analysts covering Alumasc Group PLC (LON:ALU), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alumasc Group PLC has GBX 300 highest and GBX 190 lowest target. GBX 253.33’s average target is 45.17% above currents GBX 174.5 stock price. Alumasc Group PLC had 29 analyst reports since August 5, 2015 according to SRatingsIntel. On Tuesday, June 27 the stock rating was maintained by FinnCap with “Buy”. FinnCap maintained the shares of ALU in report on Thursday, September 1 with “Buy” rating. The firm has “Buy” rating given on Monday, July 18 by FinnCap. FinnCap maintained the stock with “Buy” rating in Tuesday, September 5 report. Peel Hunt maintained the shares of ALU in report on Tuesday, January 31 with “Buy” rating. The stock of The Alumasc Group plc (LON:ALU) has “Buy” rating given on Tuesday, February 2 by FinnCap. Canaccord Genuity initiated The Alumasc Group plc (LON:ALU) rating on Monday, January 30. Canaccord Genuity has “Buy” rating and GBX 300 target. The stock of The Alumasc Group plc (LON:ALU) earned “Buy” rating by Peel Hunt on Friday, July 1. The stock has “Buy” rating by Peel Hunt on Tuesday, October 18. The stock has “Buy” rating by FinnCap on Thursday, October 27.

The Alumasc Group plc, together with its subsidiaries, makes and sells building products in the United Kingdom, Europe, North America, the Middle East, the Far East, and internationally. The company has market cap of 62.42 million GBP. The firm offers solar shading and architectural screening products; roofing and walling products, including waterproofing systems for flat roofs and exterior wall insulation systems, as well as roofing support services; and water management solutions to manage and attenuate water originating inside or outside of the buildings. It has a 9.69 P/E ratio. It also provides housebuilding and ancillary products, such as ventilation products, access panels, doors cavity closers, and dry roof verge products.

The stock increased 1.16% or GBX 2 during the last trading session, reaching GBX 174.5. About 13,889 shares traded. The Alumasc Group plc (LON:ALU) has 0.00% since January 10, 2017 and is . It has underperformed by 16.70% the S&P500.

Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company has market cap of $40.98 million. The Company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patientÂ’s vascular condition; and WellChec, a multi-test service platform that performs tests for various chronic diseases, such as respiratory disease, vascular disease, eye disease, bone disease, heart disease, neuropathy, and diabetes. It currently has negative earnings. The companyÂ’s products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers.